Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification

Abstract excerpt

Background There is significant interest in treatment de-escalation for human papillomavirus-associated (HPV + ) oropharyngeal squamous cell carcinoma (OPSCC) patients given the generally favourable prognosis. However, 15–30% of patients recur after primary treatment, reflecting a need for improved risk-stratification tools. We sought to develop a molecular test to risk stratify HPV + OPSCC patients. Methods We...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Head and Neck Cancer Studies
• Share to Inflammatory Biomarkers in Disease Prognosis
• Share to Salivary Gland Disorders and Functions